Acute-phase serum amyloid a protein andits implication inthedevelopment of type 2 diabetes in the KORA S4/F4 study

Diabetes Care

Volumn 36, Issue 5, 2013, Pages 1321-1326

  Marzi, Carola ^a,b   Huth, Cornelia ^a,b   Herder, Christian ^c   Baumert, Jens ^a,b   Thorand, Barbara ^a,b   Rathmann, Wolfgang ^c   Meisinger, Christa ^a,b   Wichmann, H Erich ^a   Roden, Michael ^c   Peters, Annette ^a,b   Grallert, Harald ^a,b   Koenig, Wolfgang ^d   Illig, Thomas ^a,e  

^a INSTITUTE OF EPIDEMIOLOGY   (Germany)

^b GERMAN CENTER FOR DIABETES RESEARCH DZD   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY HOSPITAL ULM   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; GLUCOSE; HEMOGLOBIN A1C; INSULIN; SERUM AMYLOID A; TRIACYLGLYCEROL;

ADULT; AGED; ALCOHOL CONSUMPTION; ARTICLE; BODY FAT; BODY MASS; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES EDUCATION; FAMILY HISTORY; FEMALE; FOLLOW UP; GLUCOSE HOMEOSTASIS; HUMAN; LEAN BODY WEIGHT; MAJOR CLINICAL STUDY; MALE; MUSCLE MASS; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL ACTIVITY; RISK ASSESSMENT; RISK FACTOR; SENSITIVITY ANALYSIS; SEX DIFFERENCE; SMOKING; SYSTOLIC BLOOD PRESSURE; WAIST HIP RATIO;

AGED; DIABETES MELLITUS, TYPE 2; FEMALE; GLUCOSE TOLERANCE TEST; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; SERUM AMYLOID A PROTEIN;

EID: 84876792518     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1514     Document Type: Article

References (26)

1. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005;48:1038-1050 (Pubitemid 40909636)
2. Pickup JC. Inflammation and activated innate immunity in the pathogenesis of type 2 diabetes. Diabetes Care 2004;27: 813-823 (Pubitemid 38280558)
3. Uhlar CM, Whitehead AS. Serum amyloid A, the major vertebrate acute-phase re-actant. Eur J Biochem 1999;265:501-523 (Pubitemid 29488982)
4. Jensen LE, Whitehead AS. Regulation of serum amyloid A protein expression during the acute-phase response. Bio-chem J 1998;334:489-503 (Pubitemid 28457193)
5. Urieli-Shoval S, Linke RP, Matzner Y. Expression and function of serum amyloid A, a major acute-phase protein, in normal and disease states. Curr Opin Hematol 2000;7:64-69 (Pubitemid 30007690)
6. Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: Association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997;40:1286-1292 (Pubitemid 27469668)
7. Mu€ller S, Martin S, Koenig W, et al. Impaired glucose tolerance is associated with increased serum concentrations of interleukin 6 and co-regulated acute-phase proteins but not TNF-alpha or its receptors. Diabetologia 2002;45:805-812
8. Sjöholm K, Lundgren M, Olsson M, Eriksson JW. Association of serum amyloid A levels with adipocyte size and serum levels of adipokines: differences between men and women. Cytokine 2009;48:260-266
9. Leinonen E, Hurt-Camejo E, Wiklund O, Hultén LM, Hiukka A, Taskinen MR. Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes. Atherosclerosis 2003;166:387-394 (Pubitemid 36071698)
10. Ley SH, Harris SB, Connelly PW, et al. Adipokines and incident type 2 diabetes in an Aboriginal Canadian [corrected] population: the Sandy Lake Health and Diabetes Project. Diabetes Care 2008;31: 1410-1415
11. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications. Part 1: Diagnosis and Classification of Diabetes Mel-litus. Report of a WHO Consultation. Geneva, World Health Org., 1999
12. Marzi C, Albrecht E, Hysi PG, et al. Genome-wide association study identifies two novel regions at 11p15.5-p13 and 1p31 with major impact on acute-phase serum amyloid A. PLoS Genet 2010;6: e1001213
13. Rathmann W, Haastert B, Icks A, et al.; KORA Study Group. Sex differencesin the associations of socioeconomic status with undiagnosed diabetes mellitus and impaired glucose tolerance in the elderly population: the KORA Survey 2000. Eur J Public Health 2005;15:627-633 (Pubitemid 41790248)
14. Rathmann W, Haastert B, Icks A, et al. High prevalence of undiagnosed diabetes mellitus in Southern Germany: target populations for efficient screening. The KORA survey 2000. Diabetologia 2003; 46:182-189 (Pubitemid 36343881)
15. Herder C, Kolb H, Koenig W, et al. Association of systemic concentrations of macrophage migration inhibitory factor with impaired glucose tolerance and type 2 diabetes: results from the Cooperative Health Research in the Region of Augsburg, Survey 4 (KORA S4). Diabetes Care 2006;29:368-371 (Pubitemid 44106520)
16. Thorand B, Baumert J, Döring A, et al.; KORA Group. Sex differences in the relation of body composition to markers of inflammation. Atherosclerosis 2006;184: 216-224 (Pubitemid 41721091)
17. Kyle UG, Genton L, Hans D, Pichard C. Validation of a bioelectrical impedance analysis equation to predict appendicular skeletal muscle mass (ASMM). Clin Nutr 2003;22:537-543 (Pubitemid 37455720)
18. Kyle UG, Genton L, Karsegard L, Slosman DO, Pichard C. Single prediction equation for bioelectrical impedance analysis in adults aged 20-94 years. Nutrition 2001; 17:248-253 (Pubitemid 32366479)
19. Zhao Y, He X, Shi X, et al. Association between serum amyloid A and obesity: A meta-analysis and systematic review. Inflamm Res 2010;59:323-334
20. Trayhurn P, Beattie JH. Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 2001;60:329-339 (Pubitemid 32772448)
21. Sjöholm K, Palming J, Olofsson LE, et al. A microarray search for genes predominantly expressed in human omental adipocytes: Adipose tissue as a major production site of serum amyloid A. J Clin Endocrinol Metab 2005;90:2233-2239 (Pubitemid 40586267)
22. Yang RZ, Lee MJ, Hu H, et al. Acute-phase serum amyloid A: An inflammatory adi-pokine and potential link between obesity and its metabolic complications. PLoS Med 2006;3:e287
23. Scheja L, Heese B, Zitzer H, et al. Acute-phase serum amyloid A as a marker of insulin resistance in mice. Exp Diabetes Res 2008;2008:230837
24. Carstensen M, Herder C, Kivimäki M, et al. Accelerated increase in serum in-terleukin-1 receptor antagonist starts 6 years before diagnosis of type 2 diabetes: Whitehall II prospective cohort study. Diabetes 2010;59:1222-1227
25. Thorand B, Baumert J, Kolb H, et al. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. Diabetes Care 2007;30:854-860 (Pubitemid 46556577)
26. Danesh J, Kaptoge S, Mann AG, et al. Long-term interleukin-6 levels and subsequent risk of coronary heart disease: two new prospective studies and a systematic review. PLoS Med 2008;5:e78